
Development of GI-Safe NSAIDs




Hydrogen Sulfide is an Anti-Inflammatory, Pro-Healing Molecule



Nature Reviews Drug Discovery


H₂S-Releasing Anti-Inflammatory Drugs



- 30 million people take NSAIDs on a daily basis
- 15.3 deaths per 100,000 users


Unmet Medical Need

H₂S-Releasing Anti-Inflammatory Drugs





H₂S-Releasing Anti-Inflammatory Drugs







Effectiveness of ATB-346 compared to naproxen in adjuvant-arthritic rats

Study performed in a blind manner by independent contractor in France












What About GI Safety?


ATB-346 Causes Negligible Gastric Damage (even at a very high dose)











Phase 1 Trial

Single Ascending Doses (each cohort has 6 on drug and 2 on placebo)

First cohort: 25 mg single dose 75 mg single dose 150 mg single dose 300 mg single dose 500 mg single dose 1000 mg single dose 1500 mg single dose 2000 mg single dose

Fed vs fasted 750 mg single dose



Phase 1 Trial

Multiple Ascending Doses

250 mg once-daily for 14 days750 mg once-daily for 14 days750 mg twice-daily for 14 days

Naproxen dose for arthritis: 500 mg twice-daily



Phase 1 Trial Results

25 mg to 2,000 mg single doses were safe and well-tolerated


250 mg daily (14 days) – safe and well-tolerated



Antibe Therapeutics Subject #357 had prior history of hepatitis and was found to have a gallstone lodged in his bile duct when examined on Day 17 of this trial


Phase 1 Trial

What about pharmacodynamics?



Phase 1 Trial

Enhanced suppression of COX activity vs naproxen Longer duration of suppression of COX activity







Phase 2 Trial

10-day treatment 250 mg once daily WOMAC
12 patients with osteoarthritis of the knee
Started - April 2016 Toronto
Completed – August 2016





Inhibition of Thromboxane Synthesis by ATB-346 in OA Patients



Is ATB-346 GI-Safe in Humans at an Effective Anti-Inflammatory Dose?

Phase 2B Endoscopy Trial

~120 healthy volunteers per group

500 mg naproxen twice daily vs 160 mg ATB-346 once daily


14 days of drug treatment

Upper GI endoscopy prior to study and on day 14

Primary endpoint: number of upper GI ulcers

Study powered based on a predicted ulcer rate of 20 in the naproxen group and 7 in the ATB-346 group

Primary endpoint results were released on Monday March 19



SUMMARY

Linking an H₂S-releasing moiety to an NSAID:

• substantially reduces GI toxicity (animals & humans)

Thank you !

Giuseppe Cirino Jason McDougall Marcelo Muscara Gilberto de Nucci Andre Buret Wally MacNaughton - University of Calgary Jose G Ferraz

- University of Naples - Dalhousie University - University of Sao Paulo - University of Campinas - University of Calgary - University of Calgary

> Jane Mitchell Derek Gilroy Rod Flower Mauro Perretti

- Imperial College - UCL - QMUL - QMUL